Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

NCT01474681 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelocytic Leukemia
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Marginal Zone Lymphoma
Follicular Lymphomas
Large-cell Lymphoma
Lymphoblastic Lymphoma
Burkitt's Lymphoma
High Grade Lymphomas
Mantle-cell Lymphoma
Lymphoplasmacytic Lymphoma

Interventions

BIOLOGICAL: HSC835

Sponsor

Novartis Pharmaceuticals